Table 3.
Effect of liquid formulation composition on equilibrium solubility, droplet size, and zeta potential
| No. | LFCS type | Formulation | Solubility (mg/g)* | 85% Drug load (mg/g) | Droplet size (nm)* | Zeta potential (mV)* |
|---|---|---|---|---|---|---|
| F1 | I | MCT | 0.6±0.1 | 0.5 | 43,355±700 | −24.3±3.7 |
| F2 | II | MCT:I988 (7:3)/TO106V (1/1) | 8.6±0.4 | 7.3 | 1120±81 | −3.0±0.5 |
| F3 | IIIA | MCT:I988 (7:3)/HCO-30 (1/1) | 6.6±0.1 | 5.6 | 52.8±3.2 | −19.4±5.9 |
| F4 | IIIB | CMCM/HCO-30 (1/1) | 19.1±0.7 | 16.3 | 149.9±2.5 | −26.7±2.7 |
| F5 | IIIB | CMCM:TC(1:1)/HCO-30 (1/1) | 23.2±0.7 | 19.7 | 109.5±1.2 | −26.4±2.8 |
| F6 | IV | TC | 30.7±1.3 | 26.1 | 175±3.3 | 2.0±2.4 |
Notes: *Data are expressed as mean±SD, n=3–6.
Abbreviations: LFCS, lipid formulation classification system; MCT, medium chain triglycerides represented by Cremercoor® MCT 70/30; I988, Mixture of medium chain mono and diglycerides represented by Imwitor988, CMCM: Medium chain mono & diglycerides c8-10 (monoglycerides 80%) represented by Capmul MCM; TC, Transcutol.